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BeOBJECTIVES This study sought to test the hypothesis that end-systolic volume (ESV), as a marker of severity of left
ventricular (LV) remodeling, inﬂuences the relationship between myocardial viability and survival in patients with cor-
onary artery disease and LV systolic dysfunction.
BACKGROUND Retrospective studies of ischemic LV dysfunction suggest that the severity of LV remodeling deter-
mines whether myocardial viability predicts improved survival with surgical compared with medical therapy, with
coronary artery bypass grafting (CABG) only beneﬁtting patients with viable myocardium who have smaller ESV.
However, this has not been tested prospectively.
METHODS Interactions of end-systolic volume index (ESVI), myocardial viability, and treatment with respect to survival
were assessed in patients in the prospective randomized STICH (Comparison of Surgical and Medical Treatment for Congestive
Heart Failure and Coronary Artery Disease) trial of CABG versus medical therapy who underwent viability assessment (n ¼
601; age 61  9 years; ejection fraction #35%), with a median follow-up of 5.1 years. Median ESVI was 84 ml/m2. Viability
was assessed by single-photon emission computed tomography or dobutamine echocardiography using pre-speciﬁed criteria.
RESULTS Mortality was highest among patients with larger ESVI and nonviability (p < 0.001), but no interaction was
observed between ESVI, viability status, and treatment assignment (p ¼ 0.491). Speciﬁcally, the effect of CABG versus
medical therapy in patients with viable myocardium and ESVI #84 ml/m2 (hazard ratio [HR]: 0.85; 95% conﬁdence in-
terval [CI]: 0.56 to 1.29) was no different than in patients with viability and ESVI >84 ml/m2 (HR: 0.87; 95% CI: 0.57 to
1.31). Other ESVI thresholds yielded similar results, including ESVI #60 ml/m2 (HR: 0.87; 95% CI: 0.44 to 1.74). ESVI and
viability assessed as continuous rather than dichotomous variables yielded similar results (p ¼ 0.562).
CONCLUSIONS Among patients with ischemic cardiomyopathy, those with greater LV ESVI and no substantial viability
had worse prognosis. However, the effect of CABG relative to medical therapy was not differentially inﬂuenced by the
combination of these 2 factors. Lower ESVI did not identify patients in whom myocardial viability predicted better
outcome with CABG relative to medical therapy. (Comparison of Surgical and Medical Treatment for Congestive Heart
Failure and Coronary Artery Disease [STICH]; NCT00023595) (J Am Coll Cardiol Img 2015;8:1121–9)
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1122D espite advances in diagnosis andtreatment, heart failure remains asubstantial cause of death and
disability (1,2), driven importantly by the
causal role of coronary artery disease (CAD)
in the development of left ventricular (LV)
dysfunction (3). LV systolic dysfunction in
the setting of CAD is not always an irrever-
sible process because LV function may
improve substantially with beta-blocker ther-
apy, cardiac resynchronization, and revascu-
larization (3–7). LV function is most likely to
improve with medical, device, or surgical
therapies in patients with viable myocardium
identiﬁed using noninvasive imaging (4,8–14).
Many previous studies, primarily retrospec-tive and performed before the advent of beta-
blockers for LV systolic dysfunction, suggested that
myocardial viability also identiﬁed patients in whom
survival is enhanced with revascularization compared
with medical management (8,15,16). In contradistinc-
tion, the prospective STICH (Comparison of Surgical
and Medical Treatment for Congestive Heart Failure
and Coronary Artery Disease) trial, which randomized
patients with CAD and LV dysfunction to evidence-
based medical therapy or coronary artery bypass graft
(CABG) surgery plus medical therapy, demonstrated
no interaction between myocardial viability and treat-
ment strategy with respect to survival (17).SEE PAGE 1130Previous retrospective studies of patients with
ischemic LV dysfunction have suggested that the
severity of LV remodeling affects the relation be-
tween myocardial viability and survival with CABG,
such that patients with marked LV dilation (i.e., large
end-systolic volume [ESV]) develop irreversible
remodeling to the extent that viable myocardium, if
present, does not contribute to improved LV function
or improved survival with revascularization. Accord-
ing to this concept, the beneﬁcial effect of CABG on
LV functional recovery and survival would thusa, Canada; zzMedical University of Lodz, Lodz, Poland; xxMedical
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smaller ESV (18–21). This theory is plausible but
has not been tested prospectively with random allo-
cation of treatment strategies. The current study
investigated the impact of LV remodeling on the
relationship between myocardial viability, treatment
with revascularization versus medical management,
and survival in patients enrolled in the STICH trial.
METHODS
PATIENT ENROLLMENT. Design and enrollment
criteria for the STICH study and STICH viability sub-
study have been reported in detail (17,22,23). The
STICH study is a multicenter, nonblinded, random-
ized trial funded by the National Heart, Lung, and
Blood Institute (NHLBI). The study of revasculariza-
tion versus medical therapy was conducted at 99 sites
in 22 countries. Patients with angiographic docu-
mentation of CAD amenable to surgical revasculari-
zation and LV ejection fraction (EF) #35% were
eligible for enrollment. Exclusion criteria included
left main coronary stenosis >50%, cardiogenic shock,
myocardial infarction within 3 months, and need for
aortic valve surgery. All participants provided written
informed consent. Patients were randomized to
receive medical therapy alone or medical therapy plus
CABG. A “risk at randomization” score was calculated
for each patient using a statistical model derived in an
independent dataset from multiple variables with
known power to predict 5-year risk of death without
CABG (24). Medical therapy was excellent, with $90%
of patients receiving statins, beta-blockers, and either
angiotensin-converting enzyme inhibitors or angio-
tensin receptor blockers at 1 year and 88% receiving
aspirin ($92% received either aspirin or warfarin) (23).
VIABILITY TESTING. Of the 1,212 enrolled patients,
601 underwent viability testing. Details regarding pa-
tient selection for imaging have been reported previ-
ously (17). Viability was assessed using single-photon
computed tomography (SPECT) in 471 patients
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1123150 patients were studied by use of both techniques.
For SPECT, 4 protocols for assessing myocardial
viability were permitted at the enrolling sites, in-
cluding thallium imaging using a rest-redistribution
or stress-rest-reinjection protocol, rest-redistribution
thallium imaging, or imaging with a technetium-99m
tracer at rest after administration of nitroglycerin.
For echocardiography, imaging was performed at rest
and during staged infusions of dobutamine starting at
5 mg/kg/min and increasing to 10, 20, 30, and40 mg/kg/min
in 3- to 5-min intervals.
Independent NHLBI-funded core laboratories (22)
blinded to patient details and treatment assignment
coordinated data collection and analysis for the
SPECT and dobutamine echocardiography studies.
Thresholds of viable myocardium were pre-speciﬁed
to classify patients in a binary fashion as being with
or without substantial myocardial viability. Viability
was also evaluated as a continuous variable. Core
laboratory measurements were submitted to the Duke
Clinical Research Institute, which performed all sta-
tistical analyses.
For SPECT, patients with viability were deﬁned as
those with $11 viable segments based on relative
tracer activity using a 17-segment model. A myocar-
dial segment was deemed viable if tracer activity
was $50% of activity in the segment with maximal
activity. For thallium rest-redistribution imaging, a
segment with activity <50% of maximal myocardial
activity on the redistribution images was also deﬁned
as viable if improvement in activity from rest to
redistribution images was $12%.
For dobutamine echocardiography, patients with
viability were deﬁned as those with $5 segments with
abnormal resting systolic function manifesting con-
tractile reserve with dobutamine, using a 16-segment
model. In the 150 patients studied with both techni-
ques, based on the thresholds deﬁned above, when
both tests demonstrated viability, the sum of SPECT
plus echocardiography scores was $16 viable seg-
ments;whenboth tests demonstratednonviability, the
sumwas <16. This threshold was then applied to those
with discordant results between the 2 tests; the SPECT
viability and echocardiography viability scores were
added together, and patients were considered to have
viable myocardium when the total segment score
was $16 (17).
LV FUNCTION AND ESVs. LVEF and ESV were
measured by the independent investigators from core
laboratories blinded to treatment allocation. As pre-
viously described (25), the best available method
(based on study quality using a pre-determined hi-
erarchical algorithm) was used to measure LVEF andvolumes. The end-systolic volume index (ESVI) was
computed by dividing ESV by body surface area.
PATIENT FOLLOW-UP. After trial enrollment, pa-
tients were followed every 4 months for the ﬁrst year
and every 6 months thereafter (17,23). The primary
outcome was all-cause mortality. Secondary out-
comes included cardiovascular mortality and all-
cause mortality plus cardiovascular hospitalizations.
All endpoints were adjudicated by an independent
clinical events committee (22).
STATISTICAL METHODS. Baseline clinical character-
istics of patients were descriptively summarized using
means and SDs, unless otherwise speciﬁed. Group
characteristics at baseline were compared using the
Wilcoxon rank-sum test for continuous variables and
the conventional chi-square test or Fisher exact test
for categorical variables. Patients were initially sub-
grouped on the basis of median ESVI (84 ml/m2). The
relationships of myocardial viability, ESVI, and treat-
ment with the primary outcome of all-cause mortality
were assessed using the Cox proportional hazards
regression model and Kaplan-Meier mortality curves
(26,27). Speciﬁcally, we examined whether the effect
of CABG versus medical therapy on mortality differed
depending on viability status and ESVI by assessing
the interactions of these factors with treatment using
the Cox model. We also produced Kaplan-Meier mor-
tality curves for subgroups of patients deﬁned by
viability status and ESVI and descriptively summa-
rized CABG mortality compared with medical mortal-
ity using hazard ratios (HRs) and 95% conﬁdence
intervals (CIs) generated from the Cox model and log-
rank assessments of treatment differences. Sensitivity
analyses of the interactions between myocardial
viability, ESVI, and treatment were also performed
using different thresholds of ESVI (>90, 61 to 90,
and #60 ml/m2). Similar analyses to those described
were performed for the secondary endpoints of car-
diovascular death and death or cardiac hospitaliza-
tion. In addition to treatment comparisons of CABG
versus medical therapy as randomized (intention to
treat), supplementary analyses compared the study
arms as treated (accounting for treatment crossovers)
and per protocol (28). Finally, Cox model analyses
were performed treating viability status and ESVI as
continuous rather than binary variables.
RESULTS
Among the 601 patients undergoing viability testing,
the median ESVI was 84 ml/m2. Myocardial viability
was present in 487 patients (81%) (17). Patients
with viable myocardium had higher LVEF (27.5 
8.3% vs. 22.9  8.8%; p < 0.001) and lower ESVI
TABLE 1 Baseline Characteristics of Patients With Myocardial Viability
Patients With
LV ESVI
#84 ml/m2
(n ¼ 267)
Patients with
LV ESVI
>84 ml/m2
(n ¼ 220) p Value
Age, yrs 61  10 60  9 0.077
Prior myocardial infarction 208 (78) 165 (75) 0.452
Diabetes 115 (43) 83 (38) 0.232
Prior stroke 25 (9) 17 (8) 0.522
Hypertension 175 (66) 137 (62) 0.454
Hyperlipidemia 177 (67) 149 (68) 0.782
Current smoker 53 (20) 55 (25) 0.173
Chronic renal insufﬁciency 19 (7) 14 (6) 0.734
Atrial ﬂutter/ﬁbrillation 42 (16) 32 (15) 0.717
Peripheral vascular disease 45 (17) 30 (14) 0.328
RAR score* 12  9 13  8 0.140
Previous CABG 5 (2) 7 (3) 0.354
Bypass graft status
$1 stenosed or occluded 4 (80) 7 (100)
$1 occluded 4 (80) 6 (86)
Previous PCI 43 (16) 34 (16) 0.845
CAD distribution
No. of diseased vessels $75% 0.162
0 6 (2) 3 (1)
1 77 (29) 47 (22)
2 91 (34) 88 (40)
3 93 (35) 81 (37)
Proximal LAD stenosis $75% 170 (64) 139 (64) 0.964
Left main stenosis ($50%) 8 (3) 4 (2) 0.408
Highest NYHA functional class within 3 months 0.002
I 14 (5) 10 (5)
II 114 (43) 68 (31)
III 110 (41) 101 (46)
IV 29 (11) 41 (19)
Medications at baseline
Beta-blocker 235 (88) 202 (92) 0.169
ACE inhibitor 223 (84) 189 (86) 0.467
ARB 21 (8) 19 (9) 0.758
ACE inhibitor or ARB 242 (91) 204 (93) 0.408
Statin 227 (85) 178 (81) 0.228
Aspirin 227 (85) 187 (85) 0.995
Blood pressure, mm Hg
Systolic 123  19 119  16 0.029
Diastolic 75  11 75  11 0.564
Heart rate, beats/min 72  11 75  13 0.074
LV ejection fraction, % 33  8 23  6 <0.001
LV EDVI, ml/m2 94  21 145  31 <0.001
LV ESVI, ml/m2 63  15 111  24 —
Hemoglobin, g/dl 14  2 14  2 0.195
Creatinine, mg/dl 1.2  1.0 1.1  0.3 0.573
BUN, mg/dl 30  21 29  19 0.540
Values are mean  SD or n (%). *The RAR score ranges from 1 to 32, with higher numbers indicating a higher
predicted rate of death. Among patients receiving medical therapy, a score of 1 predicts a rate of 18% and a score
of 32 predicts a rate of 99% over 5 years.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; BUN ¼ blood urea nitrogen;
CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; EDVI ¼ end-diastolic volume index;
ESVI ¼ end-systolic volume index; LAD ¼ left anterior descending coronary artery; LV ¼ left ventricular;
NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary intervention; RAR ¼ risk at randomization.
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1124(84.5  30.9 ml/m2 vs. 107.7  43.5 ml/m2; p < 0.001)
than those without myocardial viability. ESVI did not
differ between patients undergoing CABG versus
medical therapy (88.7  33.9 ml/m2 vs. 89.1  35.7
ml/m2; p ¼ 0.820). Baseline characteristics of patients
with viable myocardium, comparing those with ESVI
above and below the median value, are presented in
Table 1, and characteristics of patients without viable
myocardium are presented in Table 2. Among patients
with myocardial viability, those with ESVI >84 ml/m2
had more severe symptoms, lower LVEF, and higher
LV end-diastolic volume index but otherwise did not
differ from those with lower ESVI.
For the entire group, there was no interaction be-
tween ESVI, viability status, and treatment assign-
ment to CABG versus medical therapy with respect to
survival (p ¼ 0.491). Among the 487 patients with
viable myocardium (Figure 1), no interaction was
observed between ESVI and treatment assignment
with respect to survival (p ¼ 0.962). Speciﬁcally, the
effect of CABG compared with medical therapy in
patients with ESVI #84 ml/m2 (HR: 0.85; 95% CI: 0.56
to 1.29) was not different than that of patients with
ESVI >84 ml/m2 (HR: 0.87; 95% CI: 0.57 to 1.31).
Among patients with viability treated surgically,
post-operative mortality was higher in those with
high ESVI compared with low ESVI (37.7% vs. 25.8% at
5 years) (Figure 1), but this trend was not signiﬁcant
(HR: 1.30; 95% CI: 0.85 to 2.00).
An additional analysis separated the patients with
myocardial viability into 3 subgroups of ESVI (>90, 61
to 90, and #60 ml/m2). There was no difference in the
effect of CABG compared with medical therapy on
5-year mortality across the range of ESVI (Figure 2),
including the subgroup with the lowest ESVI (inter-
action p value ¼ 0.955).
Similarly, in patients with nonviable myocardium,
the effect of CABG compared with medical therapy
did not differ signiﬁcantly between patients with
ESVI #84 ml/m2 (HR: 1.30; 95% CI: 0.34 to 5.00) and
those with ESVI >84 ml/m2 (HR: 0.67; 95% CI: 0.38 to
1.20), although the number of patients with nonviable
myocardium was small, particularly among those
with lower values of ESVI.
MYOCARDIAL VIABILITY AND ESVI AS CONTINUOUS
VARIABLES. Analyses in which both myocardial
viability scores and ESVI were assessed as continuous
rather than dichotomous variables did not demon-
strate signiﬁcant interactions of viability, ESVI, and
treatment with CABG versus medical therapy on mor-
tality (p¼ 0.562). Mortality rates across the continuum
of magnitude of viable myocardium are shown in
Figure 3A, and rates across the continuum of ESVI are
shown in Figure 3B. Speciﬁcally, patients with greater
TABLE 2 Baseline Characteristics of Patients Without Myocardial Viability
Patients with
LV ESVI
#84 ml/m2
(n ¼ 37)
Patients with
LV ESVI
>84 ml/m2
(n ¼ 77) p Value
Age, yrs 64  8 60  9 0.019
Prior myocardial infarction 34 (92) 74 (96) 0.388
Diabetes 11 (30) 15 (20) 0.222
Prior stroke 3 (8) 8 (10) 1.000
Hypertension 23 (62) 28 (36) 0.010
Hyperlipidemia 30 (81) 47 (62) 0.039
Current smoker 4 (11) 14 (18) 0.312
Chronic renal insufﬁciency 3 (8) 7 (9) 1.000
Atrial ﬂutter/ﬁbrillation 3 (8) 13 (17) 0.207
Peripheral vascular disease 1 (3) 15 (20) 0.016
RAR score* 10  9 14  9 0.039
Previous CABG 1 (3) 3 (4) 1.000
Bypass graft status
$1 stenosed or occluded 1 (100) 3 (100)
$1 occluded 1 (100) 3 (100)
Previous PCI 12 (32) 15 (20) 0.128
CAD distribution
No. of diseased vessels $75% 0.835
0 0 (0) 3 (4)
1 8 (22) 20 (26)
2 17 (46) 25 (33)
3 12 (32) 29 (38)
Proximal LAD stenosis $75% 27 (73) 53 (69) 0.651
Left main stenosis ($50%) 1 (3) 1 (1) 0.546
Highest NYHA functional class within 3 months 0.349
I 2 (5) 1 (1)
II 10 (27) 20 (26)
III 21 (57) 43 (56)
IV 4 (11) 13 (17)
Medications at baseline
Beta-blocker 30 (81) 67 (87) 0.405
ACE inhibitor 32 (87) 70 (91) 0.521
ARB 2 (5) 4 (5) 1.000
ACE inhibitor or ARB 34 (92) 74 (96) 0.388
Statin 36 (97) 67 (87) 0.100
Aspirin 31 (84) 68 (88) 0.559
Blood pressure, mm Hg
Systolic 118  14 113  14 0.050
Diastolic 75  9 73  9 0.385
Heart rate, beats/min 71  11 75  16 0.190
LV ejection fraction 31  9 20  6 <0.001
LV EDVI, ml/m2 94  23 172  44 <0.001
LV ESVI, ml/m2 63  14 129  36 —
Hemoglobin, g/dl 14  2 14  1 0.401
Creatinine, mg/dl 1.1  0.3 1.2  0.4 0.074
BUN, mg/dl 26  18 28  18 0.498
Values are mean  SD or n (%). *The RAR score ranges from 1 to 32, with higher numbers indicating a higher
predicted rate of death. Among patients receiving medical therapy, a score of 1 predicts a rate of 18% and a score
of 32 predicts a rate of 99% over 5 years.
Abbreviations as in Table 1.
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1125degrees of myocardial viability and lower values of
ESVI did not manifest a signiﬁcant differential beneﬁt
of CABG over medical therapy compared with patients
with less viability and/or larger values of ESVI.
SECONDARY ENDPOINTS. Analysis of secondary
endpoints paralleled that of the primary analysis,
showing no signiﬁcant interactions of myocardial
viability, ESVI, treatment, and outcome. With respect
to cardiovascular mortality, the effect of CABG
compared with medical therapy in patients with
myocardial viability did not differ signiﬁcantly be-
tween patients with ESVI #84 ml/m2 (HR: 0.65; 95%
CI: 0.39 to 1.08) and those with ESVI >84 ml/m2 (HR:
0.88; 95% CI: 0.56 to 1.37; interaction p value ¼ 0.387).
Similarly, with the composite endpoint of mortality
plus cardiovascular hospitalizations in patients with
myocardial viability, the effect of CABG compared
with medical therapy did not differ between patients
with ESVI #84 ml/m2 (HR: 0.68; 95% CI: 0.50 to 0.92)
and those with ESVI >84 ml/m2 (HR: 0.67; 95% CI:
0.49 to 0.92; interaction p value ¼ 0.942).
ANALYSIS OF TREATMENT RECEIVED. Analysis of
actual treatment received provided similar results to
the intention-to-treat analysis for both primary and
secondary endpoints. For example, for the primary
endpoint of all-cause mortality among patients with
myocardial viability, the effect of CABG compared
with medical therapy did not differ between patients
with ESVI #84 ml/m2 (HR: 0.77; 95% CI: 0.51 to 1.16)
and those with ESVI >84 ml/m2 (HR: 0.82; 95% CI:
0.54 to 1.24; interaction p value ¼ 0.873).
DISCUSSION
The current report extends the analysis of the pro-
spective STICH myocardial viability study (17) to
examine the interaction of ESVI, as a marker of
severity of LV remodeling, with extent of myocardial
viability and treatment with CABG versus medical
therapy with respect to survival in patients with CAD
and LV systolic dysfunction. The results indicate that,
even after accounting for ESVI, speciﬁcally in patients
with lower values of ESVI, there was no signiﬁcant
interaction between viability and treatment assign-
ment with respect to survival.
The current study was inspired by previous reports
suggesting that improvement in LV function after
CABG occurs in patients with myocardial viability who
have less severe LV remodeling, whereas functional
recovery is less likely, despite viable myocardium, in
patients with severe LV remodeling. Yamaguchi et al.
(18) studied 20 patients undergoing CABG with
LVEF <30% and reported improvement in LV function
in those with ESVI <100 ml/m2 but not in those withlarger ESVI. Three other studies assessing the impact
of ESV on recovery of LV function after revasculari-
zation did not index ESV for body size. Bax et al. (19)
studied patients with mean LVEF of 29% and observed
FIGURE 1 Kaplan-Meier Analysis of Mortality Rates in Patients With Myocardial Viability
Data are shown for patients with baseline end-systolic volume index (ESVI) above and below the median value of 84 ml/m2 according to
treatment with coronary artery bypass surgery plus medical therapy (CABG) or medical therapy alone (MED). The relationship between viability,
treatment assignment, and survival was not inﬂuenced by ESVI (interaction p value ¼ 0.962).
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1126improvement in EF after CABG in patients with
smaller ESV and myocardial viability (assessed using
18F-ﬂuorodeoxyglucose [FDG] SPECT). The same in-
vestigators subsequently reported comparable results
using dobutamine echocardiography to assess viabi-
lity (20), in which the likelihood of recovery of LVEF
decreased proportionally with the increase in ESV
despite the presence of viable myocardium. Similarly,
Mandegar et al. (21) reported changes in LV function
after CABG in 85 patients with EF #35% (mean 27%),
all of whom manifested myocardial viability by
dobutamine echocardiography; patients with $6
viable segments manifested improvement in EF post-
operatively, whereas patients with <6 viable seg-
ments did not increase EF if there was high ESV. Of
these 4 studies, only Bax et al. (19) reported post-
operative survival data, in which patients with
viable myocardium and small ESV had lower mortality
rates after CABG than those with viable myocardium
and high ESV (similar to trends we observed in
Figures 1 to 3 in the current study). None of these 4
studies included a comparison cohort of patients
treated with medical therapy alone.
Previous studies and meta-analyses indicating
improved survival with CABG compared with medical
therapy in patients with LV systolic dysfunction andviable myocardium are limited by retrospective
design and lack of adjustment for key baseline
comorbidities (9,15,16). Factors inﬂuencing recom-
mendations for revascularization in each patient were
not considered; hence, the subsequent analyses
ignore the biases inherent in therapeutic decisions
made by each treating physician. Moreover, the
medical therapies used are often not reported, and
when reported, would be considered suboptimal by
current standards. Speciﬁcally, beta-blockers were
underused or not used at all. Treatment with beta-
blockers has the potential to improve survival in pa-
tients with ischemic LV dysfunction (6) and to
improve LV function in those with myocardial
viability (10–12). Although patients in the STICH trial
had lower mean LVEF than patients with myo-
cardial viability treated medically in prior reports
(9,15–17), patients with viable myocardium random-
ized to medical therapy in STICH had substantially
lower annual mortality rates than patients with
viability treated medically in the previous studies.
This appears to reﬂect the adherence to guideline-
driven medical therapy in the majority of patients in
this prospective trial (29).
When myocardial viability was assessed as a
continuous variable in the current analysis (Figure 3),
FIGURE 2 Kaplan-Meier Analysis of Mortality Rates in Patients With Myocardial
Viability in 3 Subgroups of ESVI
In each subgroup, including patients with the lowest values of ESVI (#60 ml/m2), there
was no interaction of ESVI, myocardial viability, treatment with CABG plus MED versus
effects of MED alone, and mortality. HR ¼ hazard ratio; other abbreviations as in Figure 1.
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1127there was no differential effect of CABG over medical
therapy with increasing extent of viable myocardium.
These ﬁndings are supported by the previous retro-
spective study of Tarakji et al. (30), who reported
survival with medical therapy versus revasculariza-
tion in 765 patients with LVEF #35% (mean 23%).
Across the continuum of magnitude of compromised
viablemyocardium assessed by FDG positron emission
tomography (PET), there was no differential effect of
CABG with increasing extent of myocardial viability. A
subsequent study from the same institution (31) in 648
patients with CAD and LV systolic dysfunction (mean
EF 31%) studied with FDG PET did report reduced
mortality with early revascularization compared with
medical therapy as a function of increasing extent of
hibernating myocardium. However, in that study,
early revascularization was deﬁned as revasculariza-
tion within 92 days of PET, yet the survival analysis
began at 92 days, excluding all deaths before 92 days
from the analysis. Thus, early post-operative mortal-
ity, the time period of greatest hazard for CABG rela-
tive to medical therapy (23,32), was not accounted for
in the survival curves. The STICH trial results also
demonstrate a differential beneﬁt of CABG over med-
ical therapy once patients survived the ﬁrst several
months, and it is the higher early mortality risk of
CABG that produced the overall balance between sur-
gical and medical outcomes (23,32). In the current
analysis, in which early post-operative mortality was
included in the mortality analysis, no interaction be-
tween myocardial viability, ESVI, and survival with
CABG or medical therapy was observed across the
spectra of myocardial viability and ESVI (Figure 3).
STUDY LIMITATIONS. Viability assessment with
SPECT and dobutamine echocardiography does not
incorporate the particular advantages of metabolic
imaging with PET or assessment of myocardial
ﬁbrosis with cardiac magnetic resonance (31,33,34).
However, in a meta-analysis and other reviews,
SPECT and dobutamine echocardiography have had
similar prognostic potential to that of PET (9,15,16), a
small randomized study of PET versus SPECT for
viability assessment failed to show improved event-
free survival in patients assigned to PET (35), and
a randomized study of PET-guided care versus
usual care failed to demonstrate improved outcome
with the PET strategy (36). The STICH protocol was
designed in 2000 (22) before the advent of cardiac
magnetic resonance for viability assessment (8), us-
ing imaging protocols identical to those in previous
nonrandomized studies reporting survival advan-
tages of CABG over medical therapy in patients with
viable myocardium (9). As noted previously, patients
with viability data represent roughly 50% of allpatients enrolled in the STICH trial, and viability
testing was not performed on a randomly selected
subset but depended on test availability and judg-
ment of the recruiting investigator. However, previ-
ous analyses did not reveal an interaction between
performance of a viability test and treatment assign-
ment (17), which was prospective and randomized.
The majority of patients studied were deemed to have
viable myocardium based on our pre-speciﬁed
criteria. Although this limits the interpretation of
outcomes in patients with nonviable myocardium, it
provides sufﬁcient patient numbers in those with
myocardial viability to assess the interaction of ESVI
with outcomes in patients with viable myocardium.
In addition, assessment of viability as a continuous
variable (Figure 3) supports the primary analysis in
which viability was assessed as a dichotomous vari-
able. The STICH results pertain only to patients
eligible for enrollment in the STICH trial
(LVEF #35%), and the interaction of ESVI, myocardial
viability, and survival with CABG compared with
medical therapy may differ in patients with less se-
vere LV dysfunction.
FIGURE 3 Extent of Viability and ESV Expressed as Continuous Variables
(A) Five-year mortality rate plotted as a function of percentage of left ventricular myocardium demonstrating viability in patients with ESVI
above and below the median value. (B) Five-year mortality rate plotted as a function of ESVI in patients with and without myocardial viability.
Mean and 95% conﬁdence interval are shown for patients treated with CABG plus MED and MED alone. Abbreviations as in Figure 1.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Among patients with coronary artery disease and LV
systolic dysfunction, lower LV end-systolic volume
index does not identify patients in whom myocardial
viability predicts better outcome with surgical relative
to medical treatment.
TRANSLATIONAL OUTLOOK: Future research
should determine whether end-systolic volume and
myocardial viability interact to affect improvement in
LV function with surgical versus medical treatment
and determine the relation between improvement in
function and survival.
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1128The lack of signiﬁcant interaction between myo-
cardial viability and survival with surgical versus
medical management of patients with severe
ischemic LV dysfunction is reﬂected in the current
recommendations for revascularization in the 2013
American College of Cardiology/American Heart As-
sociation guideline for the management of heart fail-
ure (37), which indicates that, in the absence of angina,
CABGmay be considered, with the intent of improving
survival in patients with ischemic heart disease with
severe LV systolic dysfunction (EF <35%) whether or
not viable myocardium is present (class IIb, level of
evidence B). In contrast, other guidelines continue to
recommend that decisions for revascularization be
driven by evidence of myocardial viability (38,39). The
current data should stimulate further discussion of the
role of viability testing in determining appropriate
candidacy for revascularization.
CONCLUSIONS
The current ﬁndings indicated that patients with
ischemic LV dysfunction and extensive LV remodeling
(manifested by greater ESVI) had a worse prognosis
than those with lower ESVI. However, the effect of
CABG when added to evidence-based medical therapy
was not differentially inﬂuenced by the combinationof ESVI and extent of myocardial viability. Lower ESVI
did not identify patients in whom the presence of
viable myocardium predicted a better outcome with
CABG relative to medical therapy alone.
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